erlotinib hydrochloride has been researched along with sertraline in 1 studies
Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (sertraline) | Trials (sertraline) | Recent Studies (post-2010) (sertraline) |
---|---|---|---|---|---|
4,353 | 786 | 3,033 | 3,480 | 1,028 | 1,329 |
Protein | Taxonomy | erlotinib hydrochloride (IC50) | sertraline (IC50) |
---|---|---|---|
5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 1.083 | |
Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 0.9848 | |
Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 2.7675 | |
Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 2.6309 | |
Cytochrome P450 3A4 | Homo sapiens (human) | 0.8 | |
Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.5073 | |
Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.2888 | |
Cytochrome P450 2D6 | Homo sapiens (human) | 1.4 | |
Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 1.2882 | |
Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | 8.3173 | |
Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.1814 | |
Alpha-2C adrenergic receptor | Homo sapiens (human) | 4.477 | |
D | Rattus norvegicus (Norway rat) | 0.26 | |
D(3) dopamine receptor | Rattus norvegicus (Norway rat) | 0.26 | |
Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 0.8783 | |
Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | 0.825 | |
D(1B) dopamine receptor | Rattus norvegicus (Norway rat) | 0.26 | |
5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 2.7409 | |
5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 1.083 | |
D(4) dopamine receptor | Rattus norvegicus (Norway rat) | 0.26 | |
3-oxo-5-alpha-steroid 4-dehydrogenase 2 | Homo sapiens (human) | 0.8 | |
Sodium-dependent serotonin transporter | Homo sapiens (human) | 0.0016 | |
Sodium-dependent serotonin transporter | Rattus norvegicus (Norway rat) | 0.1743 | |
Melanocortin receptor 5 | Homo sapiens (human) | 4.598 | |
Cytochrome P450 2C19 | Homo sapiens (human) | 0.655 | |
5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 3.3935 | |
D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.26 | |
Sodium-dependent dopamine transporter | Homo sapiens (human) | 0.2175 | |
Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 8.3173 | |
Nuclear receptor subfamily 3 group C member 3 | Bos taurus (cattle) | 8.3173 | |
Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 0.0697 | |
Transporter | Rattus norvegicus (Norway rat) | 0.26 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cheng, F; Jiang, X; Liu, M; Lu, W; Lv, J; Pang, X; Shen, X; Wang, Q; Zhao, Z | 1 |
1 other study(ies) available for erlotinib hydrochloride and sertraline
Article | Year |
---|---|
Repurposing sertraline sensitizes non-small cell lung cancer cells to erlotinib by inducing autophagy.
Topics: Adenylate Kinase; Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Repositioning; Drug Resistance, Neoplasm; Drug Synergism; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mice; Sertraline; Signal Transduction; Survival Analysis; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2018 |